Literature DB >> 35478158

Possible Alterations in Appetite-related Molecules After the Elimination of Hepatitis C Virus.

Yoshihiro Shimono1,2, Hirayuki Enomoto3, Nobuhiro Aizawa1, Tomoyuki Takashima1, Naoto Ikeda1, Yukihisa Yuri1, Aoi Fujiwara1, Kohei Yoshihara1, Ryota Yoshioka1, Shoki Kawata1, Shogo Ota1, Ryota Nakano1, Hideyuki Shiomi1, Takashi Nishimura1, Hiroko Iijima1.   

Abstract

BACKGROUND/AIM: Recent advances in antiviral treatment have achieved a sustained viral response (SVR) in over 95% of hepatitis C virus (HCV) infections. HCV elimination is suggested to improve several lifestyle-related factors; however, few studies have focused on dietary habit-/appetite-related factors. PATIENTS AND METHODS: HCV-infected patients who received Daclatasvir/Asnaprevir (DCV/ASV) therapy were enrolled, and the changes in appetite-related molecules after antiviral therapy were assessed with a multiple cytokine-measuring system.
RESULTS: Among 119 HCV-infected patients who received DCV/ASV treatment, 104 (87.3%) achieved an SVR. In the SVR group, DCV/ASV treatment improved several liver-related variables at 24 weeks after the completion of therapy. In patients with an SVR, the values of glucagon-like peptide 1 (GLP-1) and leptin were significantly increased at 24 weeks after completing direct-acting antiviral therapy. However, no significant change was observed in non-SVR patients, regardless of the receipt of direct-acting antiviral treatment.
CONCLUSION: Gastrointestinal hormones related to the dietary habit and/or appetite may be influenced by HCV elimination.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Chronic hepatitis C; appetite-related hormones; direct acting antiviral; sustained viral response

Mesh:

Substances:

Year:  2022        PMID: 35478158      PMCID: PMC9087057          DOI: 10.21873/invivo.12856

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  27 in total

1.  Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Takashi Nishimura; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.

Authors:  Y Shiratori; F Imazeki; M Moriyama; M Yano; Y Arakawa; O Yokosuka; T Kuroki; S Nishiguchi; M Sata; G Yamada; S Fujiyama; H Yoshida; M Omata
Journal:  Ann Intern Med       Date:  2000-04-04       Impact factor: 25.391

3.  Gut peptide hormones and pediatric type 1 diabetes mellitus.

Authors:  M Huml; J Kobr; K Siala; J Varvařovská; R Pomahačová; M Karlíková; J Sýkora
Journal:  Physiol Res       Date:  2011-05-16       Impact factor: 1.881

4.  Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus.

Authors:  Takako Inoue; Takaaki Goto; Etsuko Iio; Kayoko Matsunami; Kei Fujiwara; Noboru Shinkai; Kentaro Matsuura; Takeshi Matsui; Shunsuke Nojiri; Yasuhito Tanaka
Journal:  Hepatol Res       Date:  2017-09-22       Impact factor: 4.288

5.  Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

Authors:  Marc G Ghany; Timothy R Morgan
Journal:  Hepatology       Date:  2020-02       Impact factor: 17.425

6.  Gastrointestinal Hormone Profiles Associated With Enteral Nutrition Tolerance and Gastric Emptying in Pediatric Critical Illness: A Pilot Study.

Authors:  Enid E Martinez; Courtney Panciotti; Luis M Pereira; Mark D Kellogg; Nicholas Stylopoulos; Nilesh M Mehta
Journal:  JPEN J Parenter Enteral Nutr       Date:  2019-07-15       Impact factor: 4.016

7.  Preoperative Masseter Muscle Sarcopenia Predicts Mortality in Patients With Oesophageal Cancer.

Authors:  Teppei Kamada; Hironori Ohdaira; Eisaku Ito; Yoshinobu Fuse; Junji Takahashi; Keigo Nakashima; Yuichi Nakaseko; Masashi Yoshida; Ken Eto; Yutaka Suzuki
Journal:  Anticancer Res       Date:  2022-01       Impact factor: 2.480

8.  The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.

Authors:  Chia-Chi Wang; Kuo-Chih Tseng; I-Shiang Tzeng; Jia-Horng Kao
Journal:  J Formos Med Assoc       Date:  2020-10-29       Impact factor: 3.282

9.  The effect of meal frequency in a reduced-energy regimen on the gastrointestinal and appetite hormones in patients with type 2 diabetes: A randomised crossover study.

Authors:  Lenka Belinova; Hana Kahleova; Hana Malinska; Ondrej Topolcan; Jindra Windrichova; Olena Oliyarnyk; Ludmila Kazdova; Martin Hill; Terezie Pelikanova
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

10.  Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection.

Authors:  Zobair M Younossi; Maria Stepanova; Andrei Racila; Arian Afendy; Eric J Lawitz; Christian Schwabe; Peter J Ruane; Jay Lalezari; K Rajender Reddy; Ira M Jacobson; Andrew J Muir; Anuj Gaggar; Robert P Myers; Issah Younossi; Fatema Nader
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-31       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.